3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Head & Neck
1
Conditions
Squamous Cell Carcinoma of Head and Neck
3
Uterine Cervical Dysplasia
2
Triple Negative Breast Neoplasms
2
Prostatic Neoplasms
2
Head and Neck Neoplasms
2
Colorectal Neoplasms
2
Colonic Neoplasms
2
Vulvar Neoplasms
1
Vulvar Diseases
1
Rectal Neoplasms
1
Papillomavirus Infections
1
Ovarian Neoplasms
1
Neoplasms
1
Neoplasm Metastasis
1
Mouth Neoplasms
1
Melanoma
1
Esophageal Neoplasms
1
Carcinoma, Hepatocellular
1
Carcinoma in Situ
1
Carcinoma
1
Breast Neoplasms, Male
1
Breast Neoplasms
1
Interventions
pembrolizumab
180
Gemcitabine
168
Paclitaxel
150
Carboplatin
134
Bevacizumab
126
Cisplatin
113
Docetaxel
112
Cyclophosphamide
109
Exercise
97
Nivolumab
93
Fluorouracil
88
Capecitabine
85
Dexamethasone
81
Irinotecan
74
Radiotherapy
68
Oxaliplatin
68
Pemetrexed
66
Standard of Care
64
Leucovorin
63
Cetuximab
59
Sorafenib
53
Erlotinib Hydrochloride
53
Drug Therapy
53
Blood Specimen Collection
51
Doxorubicin
50
atezolizumab
48
trametinib
47
Ipilimumab
47
Albumin-Bound Paclitaxel
44
130-nm albumin-bound paclitaxel
42
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Interventional
×
Neoplasms
×
Indomethacin
×
Clear all
NCT02609386
2024-01-30
INSPIRE
Brooklyn ImmunoTherapeutics, LLC
Phase 2
Completed
105 enrolled
17 charts